R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: A pilot study

Giuseppe Visani, Felicetto Ferrara, Francesco Alesiani, Sonia Ronconi, Massimo Catarini, Francesca D'adamo, Barbara Guiducci, Daniele Bernardi, Sara Barulli, Pierpaolo Piccaluga, Marco Rocchi, Alessandro Isidori

Research output: Contribution to journalArticle

Abstract

We evaluated the toxicity and efficacy of nonpegylated liposomal doxorubicin (Myocet®) when substituted for conventional doxorubicin in the CHOP-21 regimen in the treatment of frail elderly patients with aggressive non-Hodgkin lymphoma. Twenty frail patients (median age, 73 years), as defined by Balducci et al., with diffuse large B cell or grade IIIb follicular lymphoma, either at diagnosis (15 patients) or relapsed (five patients), were prospectively enrolled. Nine out of 20 (45%) had a World Health Organisation (WHO) performance status ≥2. Fifteen out of 20 patients (75%) had an International Prognostic Index (IPI) score ≥3. Thirteen out of 20 (65%) evaluable patients obtained a complete response. Five additional patients (25%) achieved a partial response. With a median follow-up of 24 months (range 18-27), 15/18 responding patients (83%) are alive and disease free, as well as 3/18 are alive with active disease. Toxicity was mainly hematological with grade 3/4 neutropenia in 26% of cycles and febrile neutropenia in 5%. However, 3/20 patients presented a grade III-IV WHO toxicity (one fatal pulmonary embolism, one congestive, and one ischemic heart failure) while receiving R-COMP chemotherapy. In conclusion, R-COMP-21 is an effective regimen with promising response rates for frail and elderly patients with aggressive non-Hodgkin lymphoma.

Original languageEnglish
Pages (from-to)1081-1086
Number of pages6
JournalLeukemia and Lymphoma
Volume49
Issue number6
DOIs
Publication statusPublished - Jun 2008

Fingerprint

Frail Elderly
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Doxorubicin
Febrile Neutropenia
Follicular Lymphoma
Neutropenia
Pulmonary Embolism
B-Lymphocytes
Heart Failure

Keywords

  • Doxorubicin
  • Frail patients
  • Liposomal doxorubicin
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma : A pilot study. / Visani, Giuseppe; Ferrara, Felicetto; Alesiani, Francesco; Ronconi, Sonia; Catarini, Massimo; D'adamo, Francesca; Guiducci, Barbara; Bernardi, Daniele; Barulli, Sara; Piccaluga, Pierpaolo; Rocchi, Marco; Isidori, Alessandro.

In: Leukemia and Lymphoma, Vol. 49, No. 6, 06.2008, p. 1081-1086.

Research output: Contribution to journalArticle

Visani, G, Ferrara, F, Alesiani, F, Ronconi, S, Catarini, M, D'adamo, F, Guiducci, B, Bernardi, D, Barulli, S, Piccaluga, P, Rocchi, M & Isidori, A 2008, 'R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: A pilot study', Leukemia and Lymphoma, vol. 49, no. 6, pp. 1081-1086. https://doi.org/10.1080/10428190802043853
Visani, Giuseppe ; Ferrara, Felicetto ; Alesiani, Francesco ; Ronconi, Sonia ; Catarini, Massimo ; D'adamo, Francesca ; Guiducci, Barbara ; Bernardi, Daniele ; Barulli, Sara ; Piccaluga, Pierpaolo ; Rocchi, Marco ; Isidori, Alessandro. / R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma : A pilot study. In: Leukemia and Lymphoma. 2008 ; Vol. 49, No. 6. pp. 1081-1086.
@article{f4f5a3ad714b4bad8f0b4f46d5cc8aa5,
title = "R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: A pilot study",
abstract = "We evaluated the toxicity and efficacy of nonpegylated liposomal doxorubicin (Myocet{\circledR}) when substituted for conventional doxorubicin in the CHOP-21 regimen in the treatment of frail elderly patients with aggressive non-Hodgkin lymphoma. Twenty frail patients (median age, 73 years), as defined by Balducci et al., with diffuse large B cell or grade IIIb follicular lymphoma, either at diagnosis (15 patients) or relapsed (five patients), were prospectively enrolled. Nine out of 20 (45{\%}) had a World Health Organisation (WHO) performance status ≥2. Fifteen out of 20 patients (75{\%}) had an International Prognostic Index (IPI) score ≥3. Thirteen out of 20 (65{\%}) evaluable patients obtained a complete response. Five additional patients (25{\%}) achieved a partial response. With a median follow-up of 24 months (range 18-27), 15/18 responding patients (83{\%}) are alive and disease free, as well as 3/18 are alive with active disease. Toxicity was mainly hematological with grade 3/4 neutropenia in 26{\%} of cycles and febrile neutropenia in 5{\%}. However, 3/20 patients presented a grade III-IV WHO toxicity (one fatal pulmonary embolism, one congestive, and one ischemic heart failure) while receiving R-COMP chemotherapy. In conclusion, R-COMP-21 is an effective regimen with promising response rates for frail and elderly patients with aggressive non-Hodgkin lymphoma.",
keywords = "Doxorubicin, Frail patients, Liposomal doxorubicin, Non-Hodgkin lymphoma",
author = "Giuseppe Visani and Felicetto Ferrara and Francesco Alesiani and Sonia Ronconi and Massimo Catarini and Francesca D'adamo and Barbara Guiducci and Daniele Bernardi and Sara Barulli and Pierpaolo Piccaluga and Marco Rocchi and Alessandro Isidori",
year = "2008",
month = "6",
doi = "10.1080/10428190802043853",
language = "English",
volume = "49",
pages = "1081--1086",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma

T2 - A pilot study

AU - Visani, Giuseppe

AU - Ferrara, Felicetto

AU - Alesiani, Francesco

AU - Ronconi, Sonia

AU - Catarini, Massimo

AU - D'adamo, Francesca

AU - Guiducci, Barbara

AU - Bernardi, Daniele

AU - Barulli, Sara

AU - Piccaluga, Pierpaolo

AU - Rocchi, Marco

AU - Isidori, Alessandro

PY - 2008/6

Y1 - 2008/6

N2 - We evaluated the toxicity and efficacy of nonpegylated liposomal doxorubicin (Myocet®) when substituted for conventional doxorubicin in the CHOP-21 regimen in the treatment of frail elderly patients with aggressive non-Hodgkin lymphoma. Twenty frail patients (median age, 73 years), as defined by Balducci et al., with diffuse large B cell or grade IIIb follicular lymphoma, either at diagnosis (15 patients) or relapsed (five patients), were prospectively enrolled. Nine out of 20 (45%) had a World Health Organisation (WHO) performance status ≥2. Fifteen out of 20 patients (75%) had an International Prognostic Index (IPI) score ≥3. Thirteen out of 20 (65%) evaluable patients obtained a complete response. Five additional patients (25%) achieved a partial response. With a median follow-up of 24 months (range 18-27), 15/18 responding patients (83%) are alive and disease free, as well as 3/18 are alive with active disease. Toxicity was mainly hematological with grade 3/4 neutropenia in 26% of cycles and febrile neutropenia in 5%. However, 3/20 patients presented a grade III-IV WHO toxicity (one fatal pulmonary embolism, one congestive, and one ischemic heart failure) while receiving R-COMP chemotherapy. In conclusion, R-COMP-21 is an effective regimen with promising response rates for frail and elderly patients with aggressive non-Hodgkin lymphoma.

AB - We evaluated the toxicity and efficacy of nonpegylated liposomal doxorubicin (Myocet®) when substituted for conventional doxorubicin in the CHOP-21 regimen in the treatment of frail elderly patients with aggressive non-Hodgkin lymphoma. Twenty frail patients (median age, 73 years), as defined by Balducci et al., with diffuse large B cell or grade IIIb follicular lymphoma, either at diagnosis (15 patients) or relapsed (five patients), were prospectively enrolled. Nine out of 20 (45%) had a World Health Organisation (WHO) performance status ≥2. Fifteen out of 20 patients (75%) had an International Prognostic Index (IPI) score ≥3. Thirteen out of 20 (65%) evaluable patients obtained a complete response. Five additional patients (25%) achieved a partial response. With a median follow-up of 24 months (range 18-27), 15/18 responding patients (83%) are alive and disease free, as well as 3/18 are alive with active disease. Toxicity was mainly hematological with grade 3/4 neutropenia in 26% of cycles and febrile neutropenia in 5%. However, 3/20 patients presented a grade III-IV WHO toxicity (one fatal pulmonary embolism, one congestive, and one ischemic heart failure) while receiving R-COMP chemotherapy. In conclusion, R-COMP-21 is an effective regimen with promising response rates for frail and elderly patients with aggressive non-Hodgkin lymphoma.

KW - Doxorubicin

KW - Frail patients

KW - Liposomal doxorubicin

KW - Non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=46749125451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46749125451&partnerID=8YFLogxK

U2 - 10.1080/10428190802043853

DO - 10.1080/10428190802043853

M3 - Article

C2 - 18569635

AN - SCOPUS:46749125451

VL - 49

SP - 1081

EP - 1086

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -